

Oncology/Haematology and Transplantation



Coordinator

Sierra Gil, Jordi FGS
jsierra@santpau.cat

Members

Aljarilla Medina, Alba	IR
Álvarez Fernández, Carmen	IR
Barata Badiella, Anna	IR
Bosch Godia, Rosa Maria	IR
Briones Meijide, Javier	FGS
Brunet Mauri, Maria Salut	FGS
Caballero González, Ana Carolina	FGS
Cuellar García, Carolina	IR
De Rueda Gamboa, Maria Jèssica	IR
Escriba Garcia, Laura	IR
Garcia Cadenas, Irene	FGS
Garrido Díaz, Anna	IR
Granell Gorrochategui, Miguel	FGS
Hoyos Colell, Montserrat	IR
Martino Bofarull, Rodrigo	FGS
Miqueleiz Álamos, Sara	IR
Monter Rovira, Anna	FGS
Mora Raya, Alba	IR
Moreno Atanasio, Carolina	FGS
Novelli Canales, Silvana Ana Rina	FGS
Pallarés López, Manuel Víctor	IR
Rodríguez Fernández, Diana	IR
Rosal Muntadas-Prim, Maria Josefa	IR
Rovira Brugues, Sandra	IR
Rubio Olmos, Miguel Angel	IR
Saavedra Gerosa, Silvana Daniela	FGS
Téllez Gabriel, Marta	IR

Main Lines of Research

- ▶ Study of the molecular and cellular pathophysiology of haematological cancers.
- ▶ Study of the prognostic value of clinical and biological parameters in haematological malignancies.
- ▶ Design of new modalities of chemotherapy, biotherapy and drug treatment targeting molecular mechanisms.
- ▶ Design of new modalities of haematopoietic stem-cell transplantation and cell therapy.
- ▶ Psychological intervention and quality of life in patients with haematological malignancies.

Challenges

- ▶ Identify new prognostic parameters for risk and therapeutic stratification.
- ▶ Evaluate targeted therapy in cell lines and animal models (with the Oncogenesis and Antitumour Drugs group).
- ▶ Reduce toxicity and increase availability of allogeneic transplants.
- ▶ Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance (with the Haematology Laboratory).
- ▶ Model leukaemia and lymphoma in animals to better understand cell pathophysiology and test new drugs (with the Oncogenesis and Antitumour Drugs group).
- ▶ Molecularly characterize and determine the prognostic significance of cell pathophysiology and immunotherapy for lymphoproliferative diseases and evaluate antitumour immunotherapy in animals and humans.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Haematological Diagnosis (Dr. Josep Nomdedéu).
- ▶ Microbiology and Infectious Diseases (Dr. Pere Coll).

External Collaborations

- ▶ Carlos III Health Institute Cooperative Cancer Research Network (RTICC): J. Sierra, coordinator.

- ▶ European Research Initiative on Chronic Lymphocytic Leukemia (ERIC): C. Moreno, coordinator.
- ▶ Spanish lymphoma transplantation groups (GELTAMO): J. Briones, S. Novelli.
- ▶ Spanish haematologic malignancies consortium (PETHEMA): J. Sierra, M. Granell, S. Brunet.
- ▶ Spanish CETLAM acute myeloid leukaemia and myelodysplasia group hospitals: coordinator, S. Brunet.
- ▶ European Leukaemia Network of Excellence groups.

Active Grants

- ▶ Jordi Sierra Gil. Red Temática de Investigación Cooperativa en Cáncer (RTICC). RD12/0036/0071. Instituto de Salud Carlos III. Duration: 2013-2017. 321,500.00 €.
- ▶ Javier Briones Mejjide. Memory stem T cells transduced with a chimeric antigen receptor targeting CD30 for the treatment of hodgkin lymphoma. 20130710. Fundació La Marató de TV3. Duration: 2014-2017. 153,970.00 €.
- ▶ Jordi Sierra Gil. Grup de diagnòstic i tractament de les neoplàsies hematològiques. 2014 SGR 1281. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2017. 18,000.00 €.
- ▶ Jordi Sierra Gil. Terapia dirigida de Auristatina E o Ara-C a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. PI14/00450. Instituto de Salud Carlos III. Duration: 2015-2018. 191,500.00 €.
- ▶ Alba Mora Raya. Caracterització immunofenotípica i molecular de la malaltia residual en leucèmia limfàtica crònica. 2015 FI_B 00295. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2015-2018. 58,965.00 €.
- ▶ Javier Briones Mejjide. Terapia génica 2.0: nueva generación de vectores virales episomales de alta bioseguridad y su desarrollo pre-industrial. RTC-2015-3393-1. Ministeri d'Economia i Competitivitat. Duration: 2015-2018. 112,138.60 €.
- ▶ Javier Briones Mejjide. Advancecat: aceleradora pel desenvolupament de teràpies avançades a Catalunya. COMRDI15-1-0013. BIOCAT. Duration: 2016-2019. 39,927.96 €.
- ▶ Javier Briones Mejjide. Celulas T de memoria "STEM" transducidas con un receptor quimerico antigeno-especifico (CAR) dirigido al antigeno BCMA en linfoma de Hodgkin. PI15/01383. Instituto de Salud Carlos III. Duration: 2016-2018. 51,500.00 €.
- ▶ Carolina Moreno Atanasio. Long-term survivors in Chronic Lymphocytic Leukemia. AECC 2015-2. Associació Espanyola Contra el Càncer. Duration: 2016-2018. 20,000.00 €.
- ▶ Javier Briones Mejjide. Memory stem T cells with optimized chimeric antigen receptors targeting CD30 for the treatment of peripheral T cells lymphomas. DJCLS 10R/2016. Fundació Josep Carreras Internacional. Duration: 2017-2020. 135,000.00 €.
- ▶ Carolina Moreno Atanasio. Anàlisi de l'expressió i funció del FcγRIIb en cèl·lules B normals i en leucèmia limfàtica crònica. Conveni CELLEX-2. Fundació CELLEX. Duration: 2015-2018. 118,181.82 €.
- ▶ Javier Briones Mejjide. Inmunoterapia mediante células T de memoria "stem" modificadas con receptores quiméricos antígeno-específicos (CARs) para tratamiento de pacientes con neoplasias linfoides. Conveni CELLEX-3. Fundació CELLEX. Duration: 2015-2018. 190,000.00 €.
- ▶ Jordi Sierra Gil. Red de Terapia Celular (TerCel). RD16/0011/0028. Instituto de Salud Carlos III. Duration: 2017-2021. 3,945.00 €.
- ▶ Carolina Moreno Atanasio. Geriatric assessment in elderly patients with chronic lymphocytic leukemia. GLD16/00153. Gilead Sciences, S.L.U. Duration: 2016-2018. 32,000.00 €.
- ▶ Manuel Víctor Pallarés López. Nanoconjugados para la terapia dirigida a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. FEHH 2016. Fundació Espanyola d'Hematologia i Hemoteràpia. Duration: 2017-2018. 36,000.00 €.
- ▶ Jordi Sierra Gil. EURE-CART EUROpean Endeavour for Chimeric Antigen Receptor Therapies. H2020-SC1-PM09-EURE-CART. Unió Europea. Duration: 2017-2020. 195,552.00 €.
- ▶ Manuel Víctor Pallarés López. Contratos Sara Borrell 2013. CD13/00074. Instituto de Salud Carlos III. Duration: 2014-2017. 80,598.00 €.
- ▶ Jordi Sierra Gil. Grup de Diagnòstic i Tractament de les Neoplàsies Hematològiques. 2017 SGR 1395. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 35,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2017

- ▶ Jordi Sierra Gil, Estudio post-autorización prospectivo de terapia adaptada al riesgo en la leucemia mieloide aguda y síndromes mielodisplásicos de alto riesgo: importancia del perfil genómico y de la enfermedad residual mínima en la asignación del tratamiento. SLT002/16/00433. Departament de Salut. Duration: 2017-2019. 222,472.60 €.
- ▶ Carmen Álvarez Fernández, Inmunoterapia mediante linfocitos T de memoria STEM con receptores antígeno-específicos (CARs) en linfoma de Hodgkin. AIO 2017, Associació Espanyola Contra el Càncer. Duration: 2017-2019. 85,000.00 €.
- ▶ Jordi Sierra Gil, Implicación de la vía CXCR4/CXCL12/CXCR7 en la resistencia, recidiva y fenotipo de célula madre de la leucemia mieloide aguda. PI17/01246. Instituto de Salud Carlos III. Duration: 2018-2020. 73,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Ana Barata Badiella. Quality of life in hematopoietic cell transplantation. Universitat Autònoma de Barcelona. Directors: Jordi Sierra and Rodrigo Martino. Date of defense: 15/03/2017.
- ▶ Irene Garcia Cadenas. Complicaciones del trasplante alogénico de progenitores hematopoyéticos: enfermedad de Injerto contra el Receptor y predisposición a infecciones. Estrategias de mejora. Universitat Autònoma de Barcelona. Directors: Jordi Sierra, Rodrigo Martino. Date of defense: 30/05/2017.
- ▶ Silvana Novelli Canales. Análisis epidemiológico, clínico y anatómopatológico de los linfomas T cutáneos, Universitat Autònoma de Barcelona. Directors: Javier Briones. Date of defense: 08/11/2017.

Oncology/Haematology and Transplantation

*TIF: 386.142 **MIF: 8.045

Scientific Production

Almeida A.M., Prebet T., Itzykson R., Ramos F., Al-Ali H., Shammo J., Pinto R., Maurillo L., Wetzel J., Musto P., Van De Loosdrecht A.A., Costa M.J., Esteves S., Burgstaller S., Stauder R., Autzinger E.M., Lang A., Krippel P., Geissler D., Falantes J.F., Pedro C., Bargay J., Deben G., Garrido A., Bonanad S., Diez-Campelo M., Thepot S., Ades L., Sperr W.R., Valent P., Fenaux P., Sekeres M.A., Greil R., Pleyer L., Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study (2017) *INT J MOL SCI*, 18 (4). **IF: 3.687**

Alonso-Alvarez S., Magnano L., Alcoceba M., Andrade-Campos M., Espinosa-Lara N., Rodriguez G., Mercadal S., Carro I., Sancho J.M., Moreno M., Salar A., Garcia-Pallarols F., Arranz R., Cannata J., Terol M.J., Teruel A.I., Rodriguez A., Jimenez-Ubieto A., Gonzalez de Villambrosia S., Bello J.L., Lopez L., Monsalvo S., Novelli S., de Cabo E., Infante M.S., Pardal E., Garcia-Alvarez M., Delgado J., Gonzalez M., Martin A., Lopez-Guillermo A., Caballero M.D., Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group (2017) *BRIT J HAEMATOL*, 178 (5), 699-708. **IF: 5.128**

Bahlis N.J., Corso A., Mugge L.-O., Shen Z.-X., Desjardins P., Stoppa A.-M., Decaux O., De Revel T., Granell M., Marit G., Nahi H., Demuyck H., Huang S.-Y., Basu S., Guthrie T.H., Ervin-Haynes A., Marek J., Chen G., Facon T., Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial (2017) *LEUKEMIA*, 31 (11), 2435-2442. **IF: 10.23**

Baptista MJ, Granada I, Morgades M, Calasanz MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortuño F, García-Malo MD, Piñan MÁ, Oliveira AC, Talavera M, Buño I, Batlle-López A, Moreno C, Ferra C, Solé F. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. *AM J HE-MATOL*. 2017 Jul; 92(7): E132-E135. **IF: 5.303**

Barata A., Martino R., Gich I., Garcia-Cadenas I., Abella E., Barba P., Briones J., Brunet S., Esquirol A., Garcia-Pallarols F., Garrido A., Granell M., Martinez J., Mensa I., Novelli S., Sanchez-Gonzalez B., Valcarcel D., Sierra J., Do Patients and Physicians Agree When They Assess Quality of Life? (2017) *BIOL BLOOD MARROW TR*, 23 (6), 1005-1010. **IF: 4.484**

Barr P.M., Brown J.R., Hillmen P., O'Brien S., Barrientos J.C., Reddy N.M., Coutre S., Mulligan S.P., Jaeger U., Furman R.R., Cymbalista F., Montillo M., Dearden C., Robak T., Moreno C., Pagel J.M., Burger J.A., Suzuki S., Sukbuntherng J., Cole G., James D.F., Byrd J.C., Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL (2017) *BLOOD*, 129 (19), 2612-2615. **IF: 15.132**

Battipaglia G., Labopin M., Candoni A., Fanin R., El Cheikh J., Blaise D., Michallet M., Ruggeri A., Contentin N., Ribera J.M., Stadler M., Sierra J., Von Dem Borne P.A., Bloor A., Socie G., Nagler A., Mohty M., Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT (2017) *BONE MARROW TRANSPL*, 52 (4), 592-599. **IF: 4.497**

Bosch R., Mora A., Vicente E.P., Ferrer G., Jansa S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C., FcγRIIb expression in early stage chronic lymphocytic leukemia (2017) *LEUKEMIA LYMPHOMA*, 58 (11), 2642-2648. **IF: 2.644**

Cabrero M., Martin A., Briones J., Gayoso J., Jarque I., Lopez J., Grande C., Heras I., Arranz R., Bernal T., Perez-Lopez E., Lopez-Godino O., Conde E., Caballero D., Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial (2017) *BIOL BLOOD MARROW TR*, 23 (1), 53-59. **IF: 4.484**

Castillo N., Garcia-Cadenas I., Barba P., Canals C., Diaz-Heredia C., Martino R., Ferra C., Badell I., Elorza I., Sierra J., Valcarcel D., Querol S., Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin (2017) *BIOL BLOOD MARROW TR*, 23 (3), 491-497. **IF: 4.484**

Chen Y.-B., Wang T., Hemmer M.T., Brady C., Couriel D.R., Alousi A., Pidala J., Urbano-Ispizua A., Choi S.W., Nishihori T., Teshima T., Inamoto Y., Wirk B., Marks D.I., Abdel-Azim H., Lehmann L., Yu L., Bitan M., Cairo M.S., Qayed M., Salit R., Gale R.P., Martino R., Jaglowski S., Bajel A., Savani B., Frangoul H., Lewis I.D., Storek J., Askar M., Khar-

fan-Dabaja M.A., Aljurf M., Ringden O., Reshef R., Olsson R.F., Hashmi S., Seo S., Spitzer T.R., MacMillan M.L., Lazaryan A., Spellman S.R., Arora M., Cutler C.S., GvHD after umbilical cord blood transplantation for acute leukemia: An analysis of risk factors and effect on outcomes (2017) *BONE MARROW TRANSPL*, 52 (3), 400-408. **IF: 4.497**

De Witte T., Bowen D., Robin M., Malcovati L., Niederwieser D., Yakoub-Agha I., Mufti G.J., Fenaux P., Sanz G., Martino R., Alessandrino E.P., Onida F., Symeonidis A., Passweg J., Kobbe G., Ganser A., Platzbecker U., Finke J., Van Gelder M., Van De Loosdrecht A.A., Ljungman P., Stauder R., Volin L., Deeg H.J., Cutler C., Saber W., Champlin R., Giral S., Anasetti C., Kroger N., Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel (2017) *BLOOD*, 129 (13), 1753-1762. **IF: 15.132**

Dimopoulos M.A., Trotman J., Tedeschi A., Matous J.V., Macdonald D., Tam C., Tournilhac O., Ma S., Oriol A., Heffner L.T., Shustik C., Garcia-Sanz R., Cornell R.F., de Larrea C.F., Castillo J.J., Granell M., Kyrtsos M.-C., Leblond V., Symeonidis A., Kastiris E., Singh P., Li J., Graef T., Bilotti E., Treon S., Buske C., Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (INNOVATE): an open-label substudy of an international, multicentre, phase 3 trial (2017) *LANCET ONCOL*, 18 (2), 241-250. **IF: 36.418**

Dohner H., Estey E., Grimwade D., Amadori S., Appelbaum F.R., Buchner T., Dombret H., Ebert B.L., Fenaux P., Larson R.A., Levine R.L., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G.J., Sanz M., Sierra J., Tallman M.S., Tien H.-F., Wei A.H., Lowenberg B., Bloomfield C.D., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2017) *BLOOD*, 129 (4), 424-447. **IF: 15.132**

Escribà-García L, Alvarez-Fernández C, Telléz-Gabriel M, Sierra J, Briones J. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. *J TRANSIL MED*. 2017 May 26;15(1):115. **IF: 4.197**

Esquirol A., Pascual M.J., Ortiz M., Pinana J.L., Ferra C., Garcia Cadenas I., Vilades I., Brunet S., Martino R., Sierra J., Single-Agent GvHD prophylaxis with tacrolimus after post-Transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematologi-

*TIF: 386.142 **MIF: 8.045

cal malignancies (2017) BONE MARROW TRANSPL, 52 (9), 1273-1279.

IF: 4.497

Gallardo D., Bosch-Vizcaya A., Rodriguez-Romanos R., Santos N., Buno I., de la Camara R., Brunet S., Jimenez-Velasco A., Gonzalez M., Nieto J.B., Martinez-Laperche C., Vallejo C., Ferra C., Sampol A., Lopez-Jimenez J., Perez-Simon J.A., Martinez C., Diez J.L., Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches (2017) BIOL BLOOD MARROW TR, 23 (12), 2042-2047.

IF: 4.484

Garcia-Cadenas I., Rivera I., Martino R., Esquirol A., Barba P., Novelli S., Orti G., Briones J., Brunet S., Valcarcel D., Sierra J., Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease (2017) BONE MARROW TRANSPL, 52 (1), 107-113.

IF: 4.497

Garcia-Noblejas A., Cannata-Ortiz J., Conde E., Gonzalez Barca E., Gutierrez N., Rojas R., Vidal M.J., Ramirez M.J., Jimenez-Ubieto A., Garcia-Ruiz J.C., Sancho J.M., Lopez A., Rios Rull P., Novelli S., Albo C., Deben G., Lopez-Guillermo A., Nicolas C., Gonzalez de Villambrosia S., Mercadal S., Martin Garcia-Sancho A., Arranz R., Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO) (2017) ANN HEMATOL, 96 (8), 1323-1330.

IF: 2.845

Granell M., Calvo X., Garcia-Guinon A., Escoda L., Abella E., Martinez C.M., Teixido M., Teresa Gimenez M., Senin A., Sanz P., Campoy D., Vicent A., Arenillas L., Rosinol L., Sierra J., Blade J., De Larrea C.F., Prognostic impact of circulating plasma cells in patients with multiple myeloma: Implications for plasma cell leukemia definition (2017) HAEMATOLOGICA, 102 (6), 1099-1104.

IF: 9.090

Herrera S., Perez-Lopez J., Molto-Abad M., Guerri-Fernandez R., Cabezudo E., Novelli S., Esteve J., Hernandez A., Roig I., Solanich X., Prieto-Alhambra D., Noguez X., Diez-Perez A., Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation (2017) J BONE MINER RES, 32 (7), 1575-1581.

IF: 6.314

Jimenez-Ubieto A., Grande C., Caballero D., Yanez L., Novelli S., Hernandez-Garcia M.T., Manzanares M., Arranz R., Ferreiro J.J., Bobillo S., Mercadal S., Galeo A., Lopez Jimenez J., Moraleda J.M., Vallejo C., Albo C., Perez E., Marrero C., Magnano L., Palomera L., Jarque

I., Martinez-Sanchez P., Martin A., Coria E., Lopez-Guillermo A., Salar A., Lahuerta J.J., Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure (2017) BIOL BLOOD MARROW TR, 23 (10), 1631-1640.

IF: 4.484

Jimenez-Ubieto A., Grande C., Caballero D., Yanez L., Novelli S., Hernandez M.T., Manzanares M., Arranz R., Ferreiro J.J., Bobillo S., Mercadal S., Galeo A., Jimenez J.L., Moraleda J.M., Vallejo C., Albo C., Perez E., Marrero C., Magnano L., Palomera L., Jarque I., Coria E., Rodriguez A., Salar A., Lopez-Guillermo A., Salar A., Lahuerta J.J., Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma (2017) CANCER MED-US, 6 (12), 2766-2774.

IF: 3.202

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Orti G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017 Mar; 52(3):m438-444.

IF: 4.497

Khouri H.J., Wang T., Hemmer M.T., Couriel D., Alousi A., Cutler C., Aljurf M., Battiwalla M., Cahn J.-Y., Cairo M., Chen Y.-B., Gale R.P., Hashmi S., Hayashi R.J., Jagasia M., Juckett M., Kamble R.T., Kharfan-Dabaja M., Litzow M., Majhail N., Miller A., Nishihori T., Qayed M., Antin J.H., Schoemans H., Schouten H.C., Socie G., Storek J., Verdonck L., Vij R., Wood W.A., Yu L., Martino R., Carabasi M., Dandoy C., Gergis U., Hematti P., Solh M., Jamani K., Lehmann L., Savani B., Schultz K.R., Wirk B.M., Spellman S., Arora M., Pidala J., Improved survival after acute graft-versus-host disease diagnosis in the modern era (2017) HAEMATOLOGICA, 102 (5), 958-966.

IF: 9.090

Magnano L., Montoto S., Gonzalez-Barca E., Briones J., Sancho J.M., Muntanola A., Salar A., Besalduch J., Escoda L., Moreno C., Domingo-Domenech E., Estany C., Oriol A., Altas A., Pedro C., Gardella S., Asensio A., Vivancos P., Fernandez de Sevilla A., Ribera J.M., Colomer D., Campo E., Lopez-Guillermo A., Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a

phase 2 trial (2017) ANN HEMATOL, 96 (4), 639-646.

IF: 2.845

Martino R., Henseler A., van Lint M., Schaap N., Finke J., Beelen D., Vigouroux S., Alessandrino E.P., Mufti G.J., Veelken J.H., Bruno B., Yakoub-Agha I., Volin L., Maertens J., Or R., Leblond V., Rovira M., Kalhs P., Alvarez A.F., Vitek A., Sierra J., Wagner E., Robin M., de Witte T., Kroger N., Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes (2017) BONE MARROW TRANSPL, 52 (8), 1107-1112.

IF: 4.497

Maziarz R.T., Brazauskas R., Chen M., McLeod A.A., Martino R., Wingard J.R., Aljurf M., Battiwalla M., Dvorak C.C., Geroge B., Guinan E.C., Hale G.A., Lazarus H.M., Lee J.-W., Liesveld J.L., Ramanathan M., Reddy V., Savani B.N., Smith F.O., Strasfeld L., Taplitz R.A., Ustun C., Boeckh M.J., Gea-Banacloche J., Lindemans C.A., Auletta J.J., Riches M.L., Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: A CIBMTR study (2017) BONE MARROW TRANSPL, 52 (2), 270-278.

IF: 4.497

Montalban C., Diaz-Lopez A., Dlouhy I., Rovira J., Lopez-Guillermo A., Alonso S., Martin A., Sancho J.M., Garcia O., Sanchez J.M., Rodriguez M., Novelli S., Salar A., Gutierrez A., Rodriguez-Salazar M.J., Bastos M., Dominguez J.F., Fernandez R., Gonzalez de Villambrosia S., Queizan J.A., Cordoba R., de Ona R., Lopez-Hernandez A., Freue J.M., Garrote H., Lopez L., Martin-Moreno A.M., Rodriguez J., Abaira V., Garcia J.F., Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β 2-microglobulin yields a more accurate GELTAMO-IPI (2017) BRIT J HAEMATOL, 176 (6), 918-928.

IF: 5.128

Motllo C., Ribera J.-M., Morgades M., Granada I., Montesinos P., Brunet S., Bergua J., Tormo M., Garcia-Boyero R., Sarra J., del Potro E., Grande C., Barba P., Bernal T., Amigo M.-L., Grau J., Cervera J., Feliu E., Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols (2017) LEUKEMIA LYMPHOMA, 58 (1), 145-152.

IF: 2.644

Muffly L., Pasquini M.C., Martens M., Brazauskas R., Zhu X., Adekola K., Aljurf M.,

Oncology/Haematology and Transplantation

*TIF: 386.142 **MIF: 8.045

Scientific Production

Ballen K.K., Bajel A., Baron F., Battiwalla M., Beitinjaneh A., Cahn J.-Y., Carabasi M., Chen Y.-B., Chhabra S., Ciurea S., Copelan E., D'Souza A., Edwards J., Foran J., Freytes C.O., Fung H.C., Gale R.P., Giralte S., Hashmi S.K., Hildebrandt G.C., Ho V., Jakubowski A., Lazarus H., Luskin M.R., Martino R., Maziarz R., McCarthy P., Nishihori T., Olin R., Olsson R.F., Pawarode A., Peres E., Rezvani A.R., Rizzieri D., Savani B.N., Schouten H.C., Sallouf M., Seftel M., Seo S., Sorror M.L., Szer J., Wirk B.M., Wood W.A., Artz A., Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States (2017) *BLOOD*, 130 (9), 1156-1164.

IF: 15.132

Nomdedeu J.F., Puigdecane E., Bussaglia E., Hernandez J.J., Carricondo M., Estivill C., Marti-Tutusa J.M., Tormo M., Zamora L., Serrano E., Perea G., de Llano M.P.Q., Garcia A., Sanchez-Ortega I., Ribera J.M., Nonell L., Aventin A., Sole F., Brunet M.S., Sierra J., Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach (2017) *HEMATOLOGY ONCOLOGY*, 35 (4), 778-788.

IF: 3.193

Pallares V., Hoyos M., Chillon M.C., Barragan E., Conde M.I.P., Llop M., Cespedes M.V., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Casanova I., Mangues R., NEDD 9 an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients (2017) *ONCOTARGET*, 8 (44), 76003-76014.

IF: 5.1680

Paviglianiti A., Ruggeri A., Volt F., Sanz G., Milpied N., Furst S., Esquirol A., Arcese W., Picardi A., Ferrá C., Ifrah N., Bourhis J.H., Raj K., von dem Borne P.A., Sica S., Menard A.-I., Bloor A., Kenzly C., Gluckman E., Rocha V., Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies (2017) *BRIT J HAEMATOL*, 179 (5), 790-801.

IF: 5.128

Picleanu A.M., Novelli S., Monter A., Garcia-Cadenas I., Caballero A.C., Martino R., Esquirol A., Briones J., Sierra J., Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases (2017) *ANN HEMATOL*, 96 (5), 787-796.

IF: 2.845

Pinana J.L., Perez-Pitarch A., Garcia-cadenas I., Barba P., Hernandez-Boluda J.C., Esquirol A., Fox M.L., Terol M.J., Queraltó J.M., Vima J., Valcarcel D., Ferriols-Lisart R., Sierra J., Solano C., Martino R., A Time-to-Event Model

for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis (2017) *BIOL BLOOD MARROW TR*, 23 (7), 1177-1185.

IF: 4.484

Puiggros A., Collado R., Calasanz M.J., Ortega M., Ruiz-Xiville N., Rivas-Delgado A., Luno E., Gonzalez T., Navarro B., Garcia-Mallo M., Valiente A., Hernandez J., Ardanaz M.T., Pinan M., Blanco M.L., Hernandez-Sanchez M., Batlle-Lopez A., Salgado R., Salido M., Ferrer A., Abrisqueta P., Gimeno E., Abella E., Ferrá C., Terol M.J., Ortuno F., Costa D., Moreno C., Carbonell F., Bosch F., Delgado J., Espinet B., Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions (2017) *ONCO-TARGET*, 8 (33), 54297-54303.

IF: 5.1680

Rosinol L., Oriol A., Teruel A.I., de la Guia A.L., Blanchard M., de la Rubia J., Granell M., Sampol M., Palomera L., Gonzalez Y., Etxebeste M., Martinez-Martinez R., Hernandez M.T., de Arriba F., Alegre A., Cibeira M., Mateos M., Martinez-Lopez J., Lahuerta J.J., San Miguel J., Blade J., Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial (2017) *LEUKEMIA*, 31 (9), 1922-1927.

IF: 10.023

Rosko A.E., Wang H.-L., de Lima M., Sandmaier B., Khoury H.J., Artz A., Brammer J., Bredeson C., Farag S., Kharfan-Dabaja M., Lazarus H.M., Marks D.I., Martino Bufarull R., Mcguirk J., Mohty M., Nishihori T., Nivison-Smith I., Rashidi A., Ringden O., Seftel M., Weisdorf D., Bachanova V., Saber W., Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia (2017) *AM J HEMATOL*, 92 (1), 42-49.

IF: 5.303

Sanchez R., Ayala R., Alonso R.A., Martinez M.P., Ribera J., Garcia O., Sanchez-Pina J., Mercadal S., Montesinos P., Martino R., Barba P., Gonzalez-Campos J., Barrios M., Lavilla E., Gil C., Bernal T., Escoda L., Abella E., Amigo M.L., Moreno M.J., Bravo P., Guardia R., Hernandez-Rivas J.-M., Garcia-Guinion A., Piernas S., Ribera J.-M., Martinez-Lopez J., Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid (2017) *ANN HEMATOL*, 96 (7), 1069-1075.

IF: 2.845

Sanz J., Kwon M., Bautista G., Sanz MA, Balsalobre P, Piñana JL, Solano C, Duarte R, Ferrá C, Lorenzo I, Martín C, Barba P, Pascual MJ, Martino R, Gayoso J, Buño I, Regidor C, de la Iglesia A, Montoro J, Díez-Martín JL, Sanz GF, Cabrera R. Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia. *BLOOD ADV*. 2017 Jun 20;1(15):1047-1055.

IF: 15.132

Scheid C., De Wreede L., Van Biezen A., Koennecke C., Gohring G., Volin L., Maertens J., Finke J., Passweg J., Beelen D., Cornelissen J.J., Itala-Remes M., Chevallier P., Russell N., Petersen E., Milpied N., Richard Espiga C., Peniket A., Sierra J., Mufti G., Crawley C., Veelken J.H., Ljungman P., Cahn J.Y., Alesandrino E.P., De Witte T., Robin M., Kroger N., Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: A retrospective analysis of the EBMT chronic malignancies working party (2017) *BONE MARROW TRANSPL*, 52 (11), 1519-1525.

IF: 4.497

Schetelig J., de Wreede L.C., van Gelder M., Andersen N.S., Moreno C., Vitek A., Karas M., Michallet M., Machaczka M., Gramatzki M., Beelen D., Finke J., Delgado J., Volin L., Passweg J., Dreger P., Henseler A., van Biezen A., Bornhauser M., Schonland S.O., Kroger N., Risk factors for treatment failure after allogeneic transplantation of patients with CLL: A report from the European Society for Blood and Marrow Transplantation (2017) *BONE MARROW TRANSPL*, 52 (4), 552-560.

IF: 4.497

Schetelig J., de Wreede L.C., Andersen N.S., Moreno C., van Gelder M., Vitek A., Karas M., Michallet M., Machaczka M., Gramatzki M., Beelen D., Finke J., Delgado J., Volin L., Passweg J., Dreger P., Schaal N., Wagner E., Henseler A., van Biezen A., Bornhauser M., Iacobelli S., Putter H., Schonland S.O., Kroger N., Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) (2017) *BRIT J HAEMATOL*, 178 (4), 521-533.

IF: 5.128

Stone R.M., Mandrekar S.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Dohner K., Marcucci G., Lo-Coco F., Klisovic R.B., Wei A., Sierra J., Sanz M.A., Brandwein J.M., De Witte T., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Krauter J., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori

*TIF: 386.142 **MIF: 8.045

S., Larson R.A., Dohner H., Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation (2017) NEW ENGL J MED, 377 (5), 454-464.

IF: 79.258

Tellez-Gabriel M., Charrier C., Brounais-Le Royer B., Mullard M., Brown H.K., Verrecchia F., Heymann D., Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip (2017) EUR J CELL BIOL, 96 (2), 110-118.

IF: 2.939

Van Gelder M., De Wreede L.C., Bornhauser M., Niederwieser D., Karas M., Anderson N.S., Gramatzki M., Dreger P., Michallet M., Petersen E., et al., Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation (2017) BONE MARROW TRANSPL, 52 (3), 372-380.

IF: 4.497

Villegas A., Nunez R., Gaya A., Cuevas-Ruiz M.V., Bosch J.M., Carral A., Arrizabalaga B., Gomez-Roncero M.I., Mora A., Bravo P., Lavilla E., Monteserin C., Hernandez B., Mar-

tinez-Barranco P., Jarque I., Urquia M.A., Garcia-Donas G., Brunet S., Gonzalez F.A., Urbano A., Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry (2017) ANN HEMATOL, 96 (10), 1727-1733.

IF: 2.845